Navigation Links
Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets
Date:7/9/2008

BANNOCKBURN, Ill., July 10 /PRNewswire/ -- Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company today announced it has entered into an agreement with pharmexx to expand sales support activities in a number of countries in Western Europe. Terms of the agreement were not disclosed.

Viren Grover, Vice-Chairman of Pinnacle Biologics Inc. stated, "We are pleased to conclude this agreement with pharmexx, which allows us a cost effective way to support our sales and marketing activities for Ethyol (R) in key European markets where we believe there is upside potential."

Georg Nagl, CEO of pharmexx said, "pharmexx is delighted to be working with Pinnacle on their new venture in Europe. Our businesses are a good fit and provide an ideal win/win opportunity; we look forward to a long and successful relationship."

About Pinnacle Biologics

Founded in 2007 by former Abbott Laboratories executives Guillermo Herrera, Viren Grover, and James R. Miller, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billings and collections), pharmacovigilence, product safety, market research and administrative services.

Pinnacle holds executive offices in Bannockburn, Illinois, satellite offices in Rockville, Maryland, and Almere, The Netherlands. Further information is available at http://www.pinnaclebiologics.com

About pharmexx:

pharmexx is one of the leading contract sales organizations (CSO) world-wide. pharmexx provides pharmaceutical and biotechnology companies with creative marketing and sales solutions, and high quality sales teams.

pharmexx has developed into Europe's number one CSO operating in 53 countries and employing over 6,000 medical sales representatives and covering more than 50,000 physicians and pharmacists every day. http://www.pharmexx.com

COMPANY CONTACT:

James R. Miller, Pinnacle

President & CEO

1 (240) 372-4599


'/>"/>
SOURCE Pinnacle Biologics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group
2. Pinnacle Biologics Announces Contract With Chiltern
3. Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
4. Pinnacle Biologics Announces Opening of Executive Offices in Bannockburn, Illinois and the Addition of Sandra Miller to the Board of Directors
5. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
8. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
11. MedImmune Submits Biologics License Application to FDA for Motavizumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , February 16, 2017 ... the infusion of innovative telemedicine application, new and ... that are experiencing a boom worldwide. The healthcare ... advancement of technologies, services and new therapies for ... RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)...  Rhythm, a biopharmaceutical company developing peptide ... in life-threatening metabolic disorders, today announced the ... of financing with existing investors including Deerfield ... Associates, Pfizer Venture Investments, Third Rock Ventures, ... Rhythm will use the proceeds to advance ...
(Date:2/15/2017)... ... 2017 , ... Executive search firm, Slone Partners, announces the ... Matt is a veteran life sciences and molecular diagnostics executive with extensive commercialization ... inherited disease risk in future generations. In his new role, Matt will be ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent market research, business ... new report, Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027 ... ... Revenues of ... for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, force sensing ...
Breaking Biology News(10 mins):